12:51 PM EDT, 06/03/2024 (MT Newswires) -- Structure Therapeutics ( GPCR ) shares were up about 63% in recent Monday trading after the company reported positive 12-week topline obesity data from its phase 2a trial of GSBR-1290, with results showing a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2%.

The capsule to tablet pharmacokinetics study also yielded favorable results with up to 6.9% mean weight loss, the firm said.

GSBR-1290 showed generally favorable safety and tolerability results following repeated, daily dosing up to 120mg, it added.

Structure Therapeutics ( GPCR ) said it plans to submit an Investigational New Drug application to the US Food and Drug Administration in Q3 and to begin a phase 2b obesity study of GSBR-1290 in Q4.

Price: 55.75, Change: +21.55, Percent Change: +63.01